Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Nuclear export mediated by CRM is initiated by
2021-06-29

Nuclear export mediated by CRM1 is initiated by an interaction between RanGTP and the HEAT9 loop of CRM1, triggering a conformational change in the NES binding site that permits NES–cargo protein binding (Dong et al., 2009, Fung and Chook, 2014). Our docking simulation results predicted that DP2392-
-
The identification of CRF receptor subtypes has led
2021-06-29

The identification of CRF Phos-tag subtypes has led to a number of studies addressing its functional properties. This paper examines the evidence for CRF1 and CRF2 mediation of fear and anxiety. Recent reviews discussing specific CRF receptor functions associated with other conditions including eat
-
br Bipartite graph br Algorithm for
2021-06-29

Bipartite graph Algorithm for CFC Error detection rate and overhead evaluation Test results and discussion For verifying the proof in cb 839 from the perspective of practice, this section brings tests and analysis based on the onboard computer (OBC) of the in-service ZDPS-1A pico-satelli
-
It should also be noted that remarkable individual differenc
2021-06-29

It should also be noted that remarkable individual differences in extinguished fear bradycardia (i.e., CS+E vs. CS−E) during initial Day 2 recall test were observed, particularly within Met carriers. Exploratory analyses revealed that these individual differences were partly driven by the level of r
-
Many studies have also demonstrated that
2021-06-28

Many studies have also demonstrated that CK2 inhibition profoundly affects the PI3K/AKT pathway in different cancer models; promising results have been obtained in hematological malignancies (Buontempo et al., 2014, Borgo et al., 2013, Piazza et al., 2012, Cheong et al., 2010, Gowda et al., 2016), a
-
br Progestogens and venous thromboembolism clinical data
2021-06-28

Progestogens and venous thromboembolism: clinical data Progestogens and haemostatis: biological studies For many years, the effect of HT on haemostatis has been largely investigated in observational studies as well as in high evidence level studies among users of oral and transdermal estrogens
-
Given the molecular pharmacology and in vitro metabolism dat
2021-06-28

Given the molecular pharmacology and in vitro metabolism data, we proceeded to evaluate the in vivo pharmacokinetics of . Mice (=3) were subsequently administered a subcutaneous dose (5mg/kg) with intermittent plasma collections to measure systemic levels of (). Compound achieved a maximum plasma
-
br Ultrasonic pretreatment of substrates Substrate pretreatm
2021-06-28

Ultrasonic pretreatment of substrates Substrate pretreatment is widely used in the biofuel, textile and food industries since the substrates are always difficult to degrade. During some enzymatic hydrolysis reactions, the protective layer of the substrate impedes the reaction. Ultrasonic treatmen
-
For most enolases fluoride acts
2021-06-28

For most enolases, fluoride acts as an inhibitor, while Mg2+ is the most important metal activator. In yeast systems, metal cations and fluoride bind to enolase at the active center of the enzyme, forming a complex. The complex blocks the binding of substrates to the enzyme in yeast systems, thereby
-
Among the Ub interactions observed in the HOIP
2021-06-28

Among the ~Ub interactions observed in the HOIP structure is one that involves a RING2 domain (from the non-cognate HOIP) [47]. A similar binding interaction was defined between HHARI RING2 and the hydrophobic patch on Ub by NMR [54]. HHARI RING2 mutations that ablate the interaction inhibit formati
-
Tirapazamine australia br General mechanism of NHEJ NHEJ is
2021-06-28

General mechanism of NHEJ NHEJ is an amazingly versatile pathway that can select specific enzymes which bind to, process, and finally mediate the direct re-ligation of a wide range of DSBs including those that are complex, have incompatible ends, and contain Tirapazamine australia damages [7], [
-
A An optimized BEI SEIscore based on the trends emerged
2021-06-28

(A) An “optimized BEI-SEIscore” based on the trends, emerged from the statistical analysis of several optimization studies in pharmaceutical industry (Abad-Zapatero, 2007, Abad-Zapatero and Blasi, 2011). This type of optimized scores has been used in many previous studies. Ki=1nM at 300° K, compare
-
With regard to the DGATs we
2021-06-28

With regard to the DGATs, we have found that the majority of algal species encode at least one DGAT1, although it appears to be absent from Ostreococcus and Micromonas, as is the case for yeast, S. cerevisiae. More surprising is the presence of multiple DGAT2 genes in algae, with the exception of C.
-
In summary A is a potent orally available endothelin recepto
2021-06-25

In summary, A-216546 is a potent, orally available endothelin receptor antagonist with a high selectivity for the endothelin ETA receptor. The potency and bioavailability of A-216546 suggest that it will have important utility for preclinical evaluation of the pathophysiology of the endothelin syste
-
Erastin br Discussion br Conflicts of interest br
2021-06-25

Discussion Conflicts of interest Acknowledgment Introduction Ewing's sarcoma (EWS) is a bone cancer arising mostly in children. In 1921, EWS was originally described as “diffuse endothelioma of bone” by Dr. James R. Ewing, an American pathologist [1]. In 1992, Ewing sarcoma breakpoint re
15895 records 609/1060 page Previous Next First page 上5页 606607608609610 下5页 Last page